FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
DARMSTADT, Germany and NEW YORK, May 15, 2019 /PRNewswire/ — Not intended for US, Canada and UK-based media BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA…